4XS.HM - EXPRESS SCRIPTS HLDG

Hamburg - Hamburg Delayed Price. Currency in EUR
75.82
-0.31 (-0.41%)
As of 8:09AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close76.13
Open75.82
Bid76.23 x 0
Ask76.38 x 0
Day's Range75.82 - 75.82
52 Week Range48.03 - 76.27
Volume11
Avg. Volume0
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Should You Care About Express Scripts Holding Company’s (NASDAQ:ESRX) Cash Levels?
    Simply Wall St.5 days ago

    Should You Care About Express Scripts Holding Company’s (NASDAQ:ESRX) Cash Levels?

    Two important questions to ask before you buy Express Scripts Holding Company (NASDAQ:ESRX) is, how it makes money and how it spends its cash. What is left after investment, determinesRead More...

  • Express Scripts staking out million dollar gene therapies
    Reuters6 days ago

    Express Scripts staking out million dollar gene therapies

    Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new gene therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • Reuters6 days ago

    Focus: Express Scripts staking out million-dollar gene therapies

    Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc, Spark Therapeutics Inc and Bluebird Bio Inc to have its specialty pharmaceutical business exclusively distribute their new hemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • Options Traders Expect Huge Moves in Express Scripts (ESRX) Stock
    Zacks7 days ago

    Options Traders Expect Huge Moves in Express Scripts (ESRX) Stock

    Express Scripts (ESRX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Glenview Scores Win over Carl Icahn as ISS Supports Cigna’s Deal Plan
    Bloomberg11 days ago

    Glenview Scores Win over Carl Icahn as ISS Supports Cigna’s Deal Plan

    The recommendation is at odds with billionaire investor Carl Icahn’s efforts to drum up investor opposition to the takeover of the pharmacy benefit manager ahead of an Aug. 24 shareholder vote. Institutional Shareholder Services Inc. urged investors to support the deal. “For investors with exposure to both sides of this equation, the value proposition of a combination is straightforward: the potential benefits of the combination outweigh the risks, especially given that these risks are, to some degree, unavoidable,” ISS said in the report.

  • Glenview, Icahn Face Off Over Cigna/Express Scripts Deal
    Bloomberg12 days ago

    Glenview, Icahn Face Off Over Cigna/Express Scripts Deal

    Activist investor Carl Icahn’s push to derail Cigna Corp.’s proposed $54 billion takeover of pharmacy-benefits firm Express Scripts Holding Co. isn’t convincing one big shareholder. Glenview Capital Management LLC publicly backed the deal on Thursday in a letter to Cigna shareholders, urging other investors to do the same, saying the company is actually paying a cheap price for Express Scripts compared with similar takeovers in the past. “Sensationalist headlines and intentionally misleading assertions from those with conflicting interests and limited analysis should not carry more weight than balanced diligence,” Glenview said in 13-page letter.

  • Icahn urges Cigna shareholders to vote against Express Scripts deal
    Reuters14 days ago

    Icahn urges Cigna shareholders to vote against Express Scripts deal

    The Cigna-Express Scripts deal has drawn investor scepticism over concerns that Amazon.com Inc's (AMZN.O) entry into healthcare will upend the sector at a time when U.S. President Donald Trump has made a push to lower drug prices. "Cigna is dramatically overpaying for a highly challenged Express Scripts that is facing existential risks," Icahn wrote in an open letter about the deal.

  • Icahn urges Cigna shareholders to vote against Express Scripts deal
    Reuters14 days ago

    Icahn urges Cigna shareholders to vote against Express Scripts deal

    The Cigna-Express Scripts deal has drawn investor skepticism over concerns that Amazon.com Inc's (AMZN.O) entry into healthcare will upend the sector at a time when U.S. President Donald Trump has made a push to lower drug prices. "Cigna is dramatically overpaying for a highly challenged Express Scripts that is facing existential risks," Icahn wrote in an open letter about the deal.

  • Barrons.com14 days ago

    Icahn's Disapproval Boosts Cigna, Express Scripts

    Express Scripts Holding (ESRX) and Cigna (CI) are both trading higher on Tuesday, as activist investor Carl Icahn made his unhappiness about their proposed merger public. Express Scripts has reversed earlier losses and is trading higher on Tuesday afternoon, after activist investor Carl Icahn officially c ame out against its merger with Cigna, which is also rising.  The announcement isn't much of a surprise, as we've known for some time that Icahn was against the deal and could seek to sway investors against the deal.

  • Carl Icahn Knows It's Never Too Late to Derail a Deal
    Bloomberg14 days ago

    Carl Icahn Knows It's Never Too Late to Derail a Deal

    Carl Icahn is late to the party on Cigna Inc.’s intended $54 billion purchase of pharmacy-benefit-management giant Express Scripts Holding Co. His Tuesday letter opposing the transaction comes just weeks before an Aug. 24 shareholder vote on whether to approve it. That will make derailing the deal a tough task for the legendary activist, who owns a modest 0.56 percent of Cigna’s shares.

  • Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
    Bloomberg14 days ago

    Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019

    Express Scripts Holding Co. said it will drop 48 drugs next year from its closely watched lineup of covered therapies, including Gilead Sciences Inc.’s HIV treatment Atripla and AbbVie Inc.’s hot-selling Mavyret medicine for hepatitis C. The drug-benefit manager also won’t cover Sanofi’s hemophilia treatment Eloctate next year, it said in a statement. Express Scripts and other pharmacy-benefit managers negotiate rebates from brand-name pharmaceutical companies in exchange for including drugs on their coverage lists.

  • Cigna ‘Dramatically Overpaying’ for Express Scripts, Icahn Says
    Bloomberg14 days ago

    Cigna ‘Dramatically Overpaying’ for Express Scripts, Icahn Says

    Activist investor Carl Icahn said shareholders in Cigna Corp. should vote against the $54 billion takeover of pharmacy-benefits firm Express Scripts Holding Co. because the health insurer is “dramatically overpaying” for a company facing existential threats. “Cigna management is offering to pay an all-time high price for a company that, as a result of secular changes, is currently standing on very dangerous ground,” the billionaire wrote in an open letter to shareholders on Tuesday. Icahn disclosed a 0.56 percent stake in Cigna and said he’s betting against Express Scripts.

  • Carl Icahn Exerts Pressure on Cigna-Express Deal
    Bloomberg18 days ago

    Carl Icahn Exerts Pressure on Cigna-Express Deal

    Billionaire activist Carl Icahn's influence on Cigna Corp.'s takeover bid of Express Scripts Holding Co., was felt, but not heard on Cigna's second-quarter call with analysts. Bloomberg Opinion's Brooke ...

  • Investopedia18 days ago

    Health Insurance Carriers Headed for New Highs

    The dismantling of the Affordable Care Act (ACA), also known as Obamacare, and a deregulatory wave across affected states is underpinning profits, while the domestic focus of the health insurance companies is offering safe haven against trade war headwinds. Humana Inc. ( HUM) beat second quarter profit expectations by 18 cents while guiding fiscal year 2018 above consensus. Humana has competed with Dow component UnitedHealth Group Incorporated ( UNH) for industry leadership in recent years, matching rally leg for rally leg.

  • Investopedia19 days ago

    Icahn to Block $54B Cigna-Express Scripts Merger

    Billionaire hedge fund manager Carl Icahn has amassed a sizable stake in health insurance industry giant Cigna Corp. ( CI) and plans to vote against its proposed $54 billion acquisition of Express Scripts Holding Co.

  • ‘Icahn’ Is the Name No One Dares Speak on Cigna's Earnings Call
    Bloomberg19 days ago

    ‘Icahn’ Is the Name No One Dares Speak on Cigna's Earnings Call

    Billionaire activist Carl Icahn’s name was on everyone’s minds and no one’s lips Thursday morning when Cigna Corp. held its second-quarter earnings call with Wall Street analysts. Icahn is said to have taken a stake in the health insurer and to oppose its $54 billion takeover of Express Scripts Holding Co. His interest sent Express Scripts shares plunging and Cigna’s stock up on Wednesday as investors bet against the deal’s completion. Icahn hasn’t yet gone public with his stake, which was described by people familiar with the matter.

  • Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall
    Zacks19 days ago

    Express Scripts (ESRX) Q2 Earnings Beat, Network Claims Fall

    Express Scripts (ESRX) witnesses year-over-year decline in adjusted network claims in Q2, thanks to the loss of certain public sector clients.

  • The Wall Street Journal19 days ago

    Stocks to Watch: Tesla, Cisco, DowDuPont, T-Mobile, Wynn, Square, Wells Fargo, Clorox, Yum! Brands

    Among the companies with shares expected to trade actively in Thursday's session are Tesla, Cisco, DowDuPont, T-Mobile and Express Scripts.

  • Icahn isn't a fan of Cigna's $54B deal with Express Scripts
    American City Business Journals19 days ago

    Icahn isn't a fan of Cigna's $54B deal with Express Scripts

    The activist investor recently disrupted the planned deal between Xerox Corp. and Fujifilm Holdings.

  • The Wall Street Journal20 days ago

    [$$] Carl Icahn Has Sizable Stake in Cigna, Plans to Vote Against Express Scripts Deal

    Activist investor Carl Icahn has built a sizable stake in Cigna Corp. and plans to vote against the health insurer’s $54 billion purchase of Express Scripts Holding Co., the latest sign of trouble for the planned tie-up. Mr. Icahn, whose stake amounts to less than 5% of Cigna’s shares outstanding, believes the company is paying too high a price for the pharmacy-benefit manager, which faces threats on a number of fronts, according to people familiar with the matter. Cigna in March agreed to pay what amounted to about $96.03 a share in cash and stock for Express Scripts.

  • Associated Press20 days ago

    Express Scripts: 2Q Earnings Snapshot

    On a per-share basis, the St. Louis-based company said it had net income of $1.55. Earnings, adjusted for non-recurring costs, came to $2.22 per share. The results beat Wall Street expectations. The average ...

  • PR Newswire20 days ago

    Express Scripts Announces 2018 Second Quarter Results

    - Reports 13% Consolidated GAAP Earnings Per Diluted Share Growth - Raises Core Adjusted EBITDA Guidance Range - Increases Client Retention Level - Projects 2% to 3% Core Adjusted Claims Growth for 2019 ...

  • Icahn Opposes Cigna-Express Deal, Fearing Amazon's Drug Foray
    Bloomberg20 days ago

    Icahn Opposes Cigna-Express Deal, Fearing Amazon's Drug Foray

    Activist investor Carl Icahn has built a sizable stake in Cigna Corp. and plans to oppose the health insurer’s $54 billion takeover of pharmacy-benefits firm Express Scripts Holding Co., according to people familiar with the matter. Chief among Icahn’s concerns is that Amazon.com Inc.’s entrance into the prescription-drug industry could threaten Express Scripts’s business there over time, said the people. Express Scripts shares fell 6.3 percent to $74.44 at the close in New York, the biggest one-day drop since April 2017.

  • Will Revenue, Membership Growth Aid Cigna (CI) Q2 Earnings?
    Zacks21 days ago

    Will Revenue, Membership Growth Aid Cigna (CI) Q2 Earnings?

    Cigna (CI) Q2 earnings is likely to gain from strong growth at its segments.

  • Medical Stock Q2 Earnings Due on Aug 1: ESRX, DVA & HUM
    Zacks21 days ago

    Medical Stock Q2 Earnings Due on Aug 1: ESRX, DVA & HUM

    Solid R&D prospects likely to drive the healthcare industry in Q2 earnings.